相关实验视频
Updated: Jul 15, 2025

07:20
Inducement and Evaluation of a Murine Model of Experimental Myopia
Published on: January 22, 2019
9.9K
血清能系统在阿特罗宾的抗近视效应中的作用
Kate Thomson1, Cindy Karouta1, Daniel Weber1
1Centre for Research in Therapeutic Solutions, Faculty of Science and Technology, University of Canberra, Australia.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|September 24, 2023
概括
阿特罗平是一种近视治疗方法,通过抑制血清激素系统,可能会减缓眼睛的生长. 这项研究表明,准血清素受体可能是治疗近视而不改变血清素水平的关键.
科学领域:
- 眼科医生 眼科 眼科
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 近视 (近视) 是全球低视力的主要原因之一.
- 氨酸是近视的主要药物治疗方法.
- 氨酸的作用机制尚未完全理解,有潜在的非胆固醇标.
研究的目的:
- 为了研究血清能系统在阿特罗宾抗近视效应中的作用.
- 为了确定调节血清素活性是否会影响近视发展.
- 阐明阿特罗宾抑制近视生长的具体机制.
主要方法:
- 使用了一种近视的模型.
- 给了阿特罗平,并评估了它对近视生长的影响.
- 使用药理学药剂来刺激或对抗血清系统.
- 测量了视网膜的血清激素输出 (合成,运输,释放,代谢).
主要成果:
- 通过刺激血清系统,阿特罗宾的近视抑制作用减少了.
- 血清素受体的药理学对抗剂量依赖抑制实验近视.
- 无论是近视还是阿特罗宾治疗都没有显著改变视网膜中血清激素水平.
- 这些发现表明,阿特罗宾的抗近视作用涉及抑制血清受体活性.
结论:
- 血清的系统在近视的发展和阿特罗宾的疗效中起着重要作用.
- 调节血清受体活性可以抑制近视的进展.
- 氨酸可能通过影响血清素受体减缓近视,独立于总体血清素水平的变化.
- 这些发现对治疗近视有意义,特别是在服用血清药物的患者中.
相关概念视频
Direct-Acting Cholinergic Agonists: Pharmacological Actions
1.4K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.4K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.3K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.3K
Cholinergic Antagonists: Therapeutic Uses
769
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
769
Cholinergic Antagonists: Pharmacological Actions
1.2K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.2K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
709
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
709
Antiasthma Drugs: Muscarinic Receptor Antagonists
332
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
332

